A pair of studies found that bacteriophage therapy may treat alcoholic hepatitis and primary sclerosing cholangitis.

In a Phase II study, the drug was safe and well tolerated, and a small number of people achieved benchmarks of success against the virus.

People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.

This finding from a recent study applies to those who do not have cirrhosis when they are treated for the virus.

In a Phase IIa trial, the drug DUR-928 was associated with numerous positive outcomes after 28 days.

Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.

A U.S. appeals court upheld a judge’s previous decision to throw out a record-setting 2016 verdict in Merck’s favor.

Adults with chronic liver disease are more than twice as likely than those without the condition to have barriers to medical care.

Nevertheless, researchers are hoping to learn more from the study of the caspase inhibitor among people with non-alcoholic steatohepatitis.

A new classification system may more accurately reflect liver-related death trends in the United States.